← All trials
NCT04217967
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2020
- Primary completion
- Oct 1, 2022
- Completion date
- Oct 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Peking UniversityCollaborator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Shanxi Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.